GSK joins Boehringer and As­traZeneca in cap­ping out-of-pock­et costs for in­halers

GSK will cap out-of-pock­et costs for its in­halers at $35, mak­ing it the third ma­jor drug­mak­er to agree to lim­it pa­tients’ spend­ing amid sig­nif­i­cant US …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.